Legubicin

莱古比星

Report date: 2026/04/15 20:02:38

Base Information

Drug NameLegubicin
Drug Alias Namea prototypic substrate-based legumain prodrugQHL-108
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionDNA intercalatorsTopoisomerase II inhibitors
TargetsTopoisomerase IIDNA
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Affinity Biopharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Affinity Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A